Theralase(R) Grants Stock Options

Q: What stock options did Theralase Technologies (OTCQB: TLTFF) grant on August 7, 2026?

Theralase granted an aggregate of 7,000,000 stock options to eligible participants. According to Theralase, these options were issued under the company’s stock option plan as equity-based incentives for participants involved in its clinical and corporate activities.

Q: What is the exercise price and term of Theralase (TLTFF) stock options granted on August 7, 2026?

The granted Theralase options have an exercise price of C$0.265 per common share and a five-year term. According to Theralase, the options expire five years from the grant date, defining the window during which holders may exercise.

Q: How do the Theralase Technologies (TLTFF) stock options granted on August 7, 2026 vest?

The Theralase stock options vest over a three-year period . According to Theralase, this vesting schedule is part of its stock option plan, designed so eligible participants earn their options gradually over multiple years of continued service.

Q: Are the Theralase (OTCQB: TLTFF) August 7, 2026 stock option grants subject to TSX Venture Exchange approval?

Yes, the stock option grant is subject to acceptance by the TSX Venture Exchange . According to Theralase, completion of this grant under its stock option plan requires exchange acceptance, which is a standard condition for such equity compensation issuances.

Q: What does Theralase Technologies (TLTFF) focus on as a clinical stage company?

Theralase focuses on developing energy-activated small molecules targeting cancer, bacteria and viruses. According to Theralase, it is a clinical stage pharmaceutical company dedicated to researching and developing these molecules and related drug formulations for safe and effective disease destruction.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Theralase Technologies (TSXV: TLT, OTCQB: TLTFF) has granted an aggregate of 7,000,000 stock options under its stock option plan to eligible participants. The options have an exercise price of C$0.265 per common share, vest over three years, and expire five years from the grant date.

The grant remains subject to acceptance by the TSX Venture Exchange. Theralase describes itself as a clinical stage pharmaceutical company focused on energy-activated small molecules targeting cancer, bacteria and viruses.

Positive

Granted 7,000,000 stock options to eligible participants under the stock option plan
Options have a defined C$0.265 exercise price, providing transparent equity-based compensation terms
Three-year vesting and five-year expiry create a structured long-term incentive framework

Negative

Issuance of 7,000,000 stock options introduces potential future equity dilution for existing shareholders
Stock option grant is subject to TSX Venture Exchange acceptance, adding an approval dependency

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/07/2026 - 05:25 PM

Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options.

The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursuant to the Company's stock option plan. The options are exercisable at a price of C$0.265 per common share, vest over a three-year period and expire five years from the date of grant. The stock option grant is subject to acceptance by the TSX Venture Exchange.

About Theralase® Technologies Inc.:

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedarplus.ca.

Forward-Looking Statements

This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may", "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; access to sufficient capital to fund the Company's operations is available on terms that are commercially favourable to the Company or at all; the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

For investor information on the Company, please feel to reach out Investor Inquiries – Theralase Technologies.

For More Information:

1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/308758

FAQ

What stock options did Theralase Technologies (OTCQB: TLTFF) grant on August 7, 2026?

Theralase granted an aggregate of 7,000,000 stock options to eligible participants. According to Theralase, these options were issued under the company’s stock option plan as equity-based incentives for participants involved in its clinical and corporate activities.

What is the exercise price and term of Theralase (TLTFF) stock options granted on August 7, 2026?

The granted Theralase options have an exercise price of C$0.265 per common share and a five-year term. According to Theralase, the options expire five years from the grant date, defining the window during which holders may exercise.

How do the Theralase Technologies (TLTFF) stock options granted on August 7, 2026 vest?

The Theralase stock options vest over a three-year period. According to Theralase, this vesting schedule is part of its stock option plan, designed so eligible participants earn their options gradually over multiple years of continued service.

Are the Theralase (OTCQB: TLTFF) August 7, 2026 stock option grants subject to TSX Venture Exchange approval?

Yes, the stock option grant is subject to acceptance by the TSX Venture Exchange. According to Theralase, completion of this grant under its stock option plan requires exchange acceptance, which is a standard condition for such equity compensation issuances.

What does Theralase Technologies (TLTFF) focus on as a clinical stage company?

Theralase focuses on developing energy-activated small molecules targeting cancer, bacteria and viruses. According to Theralase, it is a clinical stage pharmaceutical company dedicated to researching and developing these molecules and related drug formulations for safe and effective disease destruction.